Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study

Table 4 Patients with a HIT-6 reduction of ≥ 5 points from baseline to month 3 (missings excluded)

	Switch patients with ≥ 5 points reduction
Total (N = 75)	38 (50.7%)
EM (N = 34)	22 (64.7%)
CM (N = 41)	16 (39.0%)

ISSN: 1129-2377